Shopping Cart
Remove All
Your shopping cart is currently empty
ATX-IN-3 is an orally active autotaxin (ATX) inhibitor with an IC50 of 46 nM. It effectively ameliorates pulmonary fibrosis in mouse models by significantly reducing collagen deposition. ATX-IN-3 demonstrates excellent metabolic stability and drug-like properties, making it suitable for research on idiopathic pulmonary fibrosis (IFP).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | ATX-IN-3 is an orally active autotaxin (ATX) inhibitor with an IC50 of 46 nM. It effectively ameliorates pulmonary fibrosis in mouse models by significantly reducing collagen deposition. ATX-IN-3 demonstrates excellent metabolic stability and drug-like properties, making it suitable for research on idiopathic pulmonary fibrosis (IFP). |
| In vitro | ATX-IN-3 (Compound 12) exhibits favorable drug-like properties, including good metabolic stability in rat liver microsomes (t 1/2 = 73.06 min, C lint = 18.97 μL/min/mg), a high drug-likeness score (1.24), and a ligand lipophilicity efficiency (LLE) value of 2.98. |
| In vivo | ATX-IN-3 (Compound 12) at a dosage of 60 mg/kg administered orally once daily for 21 consecutive days can inhibit Bleomycin-induced pulmonary fibrosis in mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.